Hotflash Inc

Share this post

BREAKING: Fezolinetant news

hotflashinc.substack.com

BREAKING: Fezolinetant news

Patience, hot flashers

Hotflash Inc
Feb 20, 2023
∙ Paid
Share

Looks like women in the US have to wait a little longer for another option to deal with hot flashes.

Astellas Pharma has announced that the US Food and Drug Administration is extending the original priority review Prescription Drug User Fee Act goal date for fezolinetant, its promising new investigational non-hormonal therapy for hot flashes.

According …

Keep reading with a 7-day free trial

Subscribe to Hotflash Inc to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
Previous
Next
© 2023 Hotflash inc
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing